These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2093633)

  • 1. With whom does the French drug industry want to work for phase I?
    Bogaievsky Y
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():207s-211s. PubMed ID: 2093633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who is responsible for what?
    Rouzioux JM
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():183s-187s. PubMed ID: 2093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Charter of medicines promotion and rational use by physicians].
    Baumevieille M; Bégaud B; Maurain C
    Therapie; 2007; 62(1):39-44. PubMed ID: 17374346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are the drug-regulatory agencies paper villains?
    Smith T
    Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251
    [No Abstract]   [Full Text] [Related]  

  • 5. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 6. Can complexity be commercialized?
    Mack GS
    Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].
    Maillols-Perroy AC; Tillet Y
    Therapie; 2012; 67(1):1-10. PubMed ID: 22487499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharma allowed to make own genetics.
    Owens J
    Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarker Development Strategies - surmounting scientific and regulatory barriers in bringing innovative medicine to market.
    Shi M
    IDrugs; 2007 Apr; 10(4):246-8. PubMed ID: 17390245
    [No Abstract]   [Full Text] [Related]  

  • 11. A regulatory and industrial perspective of the use of carbon-14 and tritium isotopes in human ADME studies.
    Dain JG; Collins JM; Robinson WT
    Pharm Res; 1994 Jun; 11(6):925-8. PubMed ID: 7937538
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug famine: possible solutions.
    Smith T
    Br Med J; 1980 Nov; 281(6253):1475-7. PubMed ID: 7437842
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical regulation in France 1980-2003.
    Paris V
    Int J Health Plann Manage; 2005; 20(4):307-28. PubMed ID: 16335080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug applications: how long to gain approval?
    Spivey RN; Lasagna L; Trimble AG
    Clin Pharmacol Ther; 1985 Apr; 37(4):361-6. PubMed ID: 3978995
    [No Abstract]   [Full Text] [Related]  

  • 15. Complementary new approaches enable repositioning of failed drug candidates.
    Tartaglia LA
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1295-8. PubMed ID: 17040191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharma 2020--An Economist Conference Shaping the Future of the Pharmaceuticals Industry.
    Kibble A
    IDrugs; 2008 May; 11(5):331-3. PubMed ID: 18465672
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic Pharmaceutical Association (GPhA) - 2008 annual meeting.
    Kuhrt K
    IDrugs; 2008 Apr; 11(4):267-70. PubMed ID: 18379960
    [No Abstract]   [Full Text] [Related]  

  • 18. The decline in new drug development.
    Rumore MM
    Am Pharm; 1992 Apr; NS32(4):73-8. PubMed ID: 1566739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
    Griffiths E; Thorpe R; Wadhwa M; Sohn Y
    Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
    [No Abstract]   [Full Text] [Related]  

  • 20. The future of drug evaluation in Australia Review of the Baume Report, a question of balance.
    Randerson DH
    Australas Biotechnol; 1991 Aug; 1(1):26-7. PubMed ID: 1367703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.